Alleviare India

  Pangraf (tacrolimus) capsules are a medication used to prevent the rejection of transplanted organs, such as the kidney or liver. The medication works by suppressing the immune system to prevent it from attacking the transplanted organ. The recommended dosage of Pangraf (tacrolimus) capsules will depend on several factors, including the patient's age, weight, overall health, and the type of organ being transplanted. Additionally, the dosage may need to be adjusted over time based on the patient's response to the medication and any side effects they may experience. In general, the starting dose of Pangraf (tacrolimus) capsules for adults is usually between 0.1 mg and 0.2 mg per kilogram of body weight per day, divided into two doses taken 12 hours apart. The maximum daily dose should not exceed 20 mg. For children, the recommended starting dose is usually between 0.15 mg and 0.3 mg per kilogram of body weight per day, divided into two doses taken 12 hours apart. The maximum

 Celsentri (maraviroc) Tablet 300mg is a medication that is used to treat HIV-1 infection in adults. It belongs to a class of drugs called CCR5 antagonists, which work by blocking the CCR5 receptor on the surface of certain immune cells. This receptor is used by the virus to enter and infect these cells, so by blocking it, Celsentri helps to prevent the virus from spreading and reproducing. Celsentri Tablet 300mg is typically used in combination with other HIV medications, such as protease inhibitors or nucleoside reverse transcriptase inhibitors (NRTIs). The combination of medications used will depend on the individual patient's condition and treatment history. Before starting Celsentri, your healthcare provider will perform a blood test to determine whether your HIV strain uses the CCR5 receptor. This is because Celsentri only works against HIV strains that use this receptor to enter cells. If your virus uses a different receptor, Celsentri will not be effective. The recommended

Bavencio (avelumab) is a medication used to treat certain types of cancer. It is a monoclonal antibody that works by binding to a protein called PD-L1, which is overproduced in some cancer cells. By binding to this protein, Bavencio helps the body's immune system to recognize and attack cancer cells, thereby slowing the progression of the disease. Bavencio 200 mg/10 ml tablets are usually administered intravenously (IV) by a healthcare professional, usually in a hospital or clinic setting. The dose and duration of treatment will depend on several factors, including the type of cancer being treated, the patient's overall health, and other medications the patient may be taking. Some common side effects of Bavencio may include fatigue, nausea, vomiting, diarrhea, decreased appetite, and skin rash. More serious side effects may also occur, including infusion reactions, immune-mediated adverse reactions, and other serious adverse events. It is important to note that Bavencio is a pr

ELAPRASE (idursulfase) is an IV infusion used to treat some of the symptoms of a genetic condition called Hunter’s syndrome, also called mucopolysaccharidosis (MYOO-koe-pol-ee-SAK-a-rye-DOE-sis). Idursulfase contains a natural enzyme that some people lack because of a genetic disorder. Elaprase helps replace this missing enzyme. ELAPRASE is a prescription medicine for patients with Hunter syndrome ELAPRASE has been shown to improve walking ability in patients 5 yrs and older. In patients 16 months to 5 yrs old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 yrs and older. It is not known if ELAPRASE is safe and effective in children under 16 months old. Hunter syndrome occurs when the body is unable to produce an enzyme called iduronate-2-sulfatase (I2S), which is responsible for breaking down GAGs. The buildup of GAGs in the body can cause a range of symptoms,